# Nosa Plugs > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/nosaplugs). ## Overview Nosa Plugs AB is a Swedish listed group built around patented slow-release technology that incorporates substances into plastic products. Through its subsidiaries, the company develops, markets and distributes niche consumer and healthcare products, including intranasal and odor-control offerings, in Europe and the United States. ## Products & services • Nozoil nasal spray and related nasal care products • Odor Control products for odor management • Microbial Control products • Smell Training products • Intranasal drug delivery platform technology • Product development, packaging and distribution - **Nasal care products** (35%) — Products such as Nozoil and related nasal-care offerings sold through pharmacy and other channels. - **Odor control products** (25%) — Products designed to reduce or manage odor-related issues for consumer and healthcare use. - **Microbial control products** (15%) — Products positioned for hygiene and microbial management applications. - **Smell training products** (10%) — Products and programs intended to support olfactory rehabilitation and training. - **Drug delivery platform** (15%) — Proprietary intranasal delivery technology used to enable new product development and licensing opportunities. - Nozoil nasal spray and related nasal care products - Odor Control products for odor management - Microbial Control products - Smell Training products - Intranasal drug delivery platform technology - Product development, packaging and distribution ## Customers Nosa sells through both B2B and B2C channels, with pharmacies, wholesalers, distributors and healthcare buyers forming the core commercial base. End customers include consumers seeking nasal-care and odor-control products, as well as healthcare and institutional users that buy through pharmacy and distribution networks. - **Pharmacies and pharmacy chains** (primary) — They buy Nozoil and consumer health products for retail and online pharmacy sales. - **Pharmaceutical wholesalers** (primary) — They distribute NOSA products into national pharmacy networks and extend market access. - **Consumers** (primary) — They purchase nasal-care, odor-control and smell-training products for personal use. - **Healthcare institutions and regions** (secondary) — They buy selected products for clinical or institutional use through procurement channels. - **Distributors and channel partners** (secondary) — They buy or resell products to build country-level coverage and market entry. - Pharmaceutical wholesalers and distributors buy for broad pharmacy reach - Pharmacies stock consumer health products for retail sale - Consumers buy nasal-care and odor-control products directly or online - Healthcare regions and institutions buy products for clinical or care use - B2B partners help expand access across country-specific pharmacy networks ## Geography The group reports sales primarily in Europe and the United States, with operations structured around selected country launches and distribution partnerships. Its commercial footprint is therefore shaped by pharmacy-channel access, local wholesaler relationships and regulatory requirements in each market. - **Europe** (70%) — Management states sales occur primarily within Europe and the USA. - **United States** (30%) — US presence is supported by the subsidiary NoseOption Inc. - Sales are concentrated in Europe and the USA - Country launches are used to build pharmacy-channel coverage - Local wholesalers expand access in each national market - The US subsidiary supports North American commercialization - Geographic mix affects regulatory, currency and distribution exposure ## Strategy Nosa’s strategy is to combine internal product development with selective acquisition of niche brands and products that can be scaled through shared sales and distribution channels. The company also focuses on expanding pharmacy distribution in Europe and validating its intranasal technology platform for future product development. - **Expand pharmacy distribution in Europe** (short-term) — Pharmacy access is central to reaching consumers efficiently and building recurring product sales. - **Develop and validate the technology platform** (medium-term) — The patented slow-release platform underpins future product innovation and potential licensing value. - **Acquire niche products and brands** (medium-term) — Acquisitions can add products that fit existing channels and improve commercial leverage. - Develop proprietary products from the intranasal technology platform - Acquire niche brands that can be scaled through shared channels - Expand pharmacy distribution country by country in Europe - Use wholesalers and distributors to accelerate market access - Build evidence for the drug-delivery platform through scientific studies ## Risks The business depends on distributors, suppliers and patent protection, so commercial execution and intellectual-property protection are central risks. As a small product company with international sales, it is also exposed to currency swings, regulatory requirements, raw-material availability and the need for ongoing financing. - **Distribution dependence** [high] — The company relies on wholesalers, pharmacies and channel partners to reach end customers. - **Patent and IP protection** [high] — Products and the platform are based on proprietary technology that may be difficult to fully protect. - **Supplier and raw-material dependence** [medium] — Manufacturing and packaging require reliable third-party inputs and logistics. - **Foreign exchange volatility** [medium] — International sales and costs create currency exposure across markets. - **Financing and liquidity needs** [high] — Product development and commercialization can require external funding before scale is reached. - Sales depend on distributor and pharmacy-channel execution - Patent protection may be incomplete for new products - Supply-chain disruptions can affect raw materials and delivery times - Foreign exchange moves can affect international sales and costs - Future funding needs depend on sales success and cash generation ## Accounting The main accounting issues are goodwill impairment, valuation of acquired intangibles and the treatment of warrants and option programs. Because the group is still building commercial scale, investors should also watch how capitalization, acquisition accounting and intra-group eliminations affect reported results and equity. - **Goodwill impairment** — Could materially affect equity and operating results - **Acquisition accounting for Pharmacure** — Affects reported asset base and earnings profile - **Warrants and share-based dilution** — Affects equity and per-share analysis - **Intra-group eliminations** — Important for understanding consolidated revenue - Goodwill from acquisitions must be tested for impairment annually - Acquired intangibles can affect amortization and future earnings - Warrants and option programs create dilution and equity accounting effects - Intra-group service revenue is eliminated at group level - IFRS reporting and estimates affect comparability across periods --- *Last updated: 2026-08-11T04:04:54.975475+00:00*